biostudies-literatureUnknown17(1)Nayak SS<h4>Background</h4>Ankylosing spondylitis (AS) is a chronic inflammatory disease associated with an increased risk of metabolic syndrome (MetS), a cluster of cardiometabolic risk factors. However, the prevalence of MetS in AS remains uncertain. This meta-analysis estimates the global prevalence of MetS in AS patients and identifies factors contributing to its variability.<h4>Methods</h4>A systematic search of PubMed, Scopus, Embase, and Web of Science was conducted for studies published up to January 18, 2024. A random-effects model was used to estimate pooled prevalence, while meta-regression and subgroup analyses explored sources of heterogeneity.<h4>Results</h4>Seventeen studies meeting the eligibility criteria were included. The pooled prevalence of MetS in AS patients was 15.5% (95% cDiabetology & metabolic syndrome158https://www.ebi.ac.uk/biostudies/studies/S-EPMC12082907biostudies-literaturePrevalence of metabolic syndrome in ankylosing spondylitis: a multi national meta-analysis study.PMC12082907Keetha NRAgyeman KBSahli YJafari MHashemi MShafi NAmini-Salehi ENayak SSJanani KVBiswas PLichahi MAfalsePrevalence of metabolic syndrome in ankylosing spondylitis: a multi national meta-analysis study.<h4>Background</h4>Ankylosing spondylitis (AS) is a chronic inflammatory disease associated with an increased risk of metabolic syndrome (MetS), a cluster of cardiometabolic risk factors. However, the prevalence of MetS in AS remains uncertain. This meta-analysis estimates the global prevalence of MetS in AS patients and identifies factors contributing to its variability.<h4>Methods</h4>A systematic search of PubMed, Scopus, Embase, and Web of Science was conducted for studies published up to January 18, 2024. A random-effects model was used to estimate pooled prevalence, while meta-regression and subgroup analyses explored sources of heterogeneity.<h4>Results</h4>Seventeen studies meeting the eligibility criteria were included. The pooled prevalence of MetS in AS patients was 15.5% (95% c2025-01-01T00:00:00Z2025 May2026-06-11T05:11:39.488Z2026-06-11T03:07:44.31ZS-EPMC120829074038027110.1186/s13098-025-01720-w